Is transvaginal mesh surgery with polytetrafluoroethylene mesh ORIHIME ® feasible for anterior pelvic organ prolapse?—Randomized comparative study between ORIHIME ® and Polyform™
Rattachement africain : jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
OBJECTIVE: Transvaginal mesh surgery for pelvic organ prolapse has been widely performed in Japan, but polypropylene mesh has not been used in Japan since the ban on TVM using polypropylene mesh in the United States. Currently, polytetrafluoroethylene mesh ORIHIME® is the only mesh available for TVM in Japan. Although polytetrafluoroethylene is a safe material, its low coefficient of friction and insufficient adhesion to the surrounding tissue make it difficult to maintain the mesh position when it is used in the transvaginal mesh surgery. The aim of this study was to evaluate the feasibility of TVM-A2 using ORIHIME®. METHODS: group (Group P). With 50 patients in each group, the complications and recurrences up to the fourth year were compared. Surgeries were performed using the TVM-A2 method. Statistical analysis was performed using EZR. RESULTS: There were no significant differences in baseline parameters between the two groups. We observed no perioperative complications, and saw one case of postoperative abscess formation in Group O, which resolved successfully after incision and drainage. The 4-year recurrence rate was significantly higher in Group O. CONCLUSION: As the recurrence rate was significantly higher in Group O, we conclude that TVM-A2 using ORIHIME® which is the same procedure as TVM-A2 using polypropylene mesh is not feasible in repairing the pelvic organ prolapse.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé, mais le titre doit être comparé manuellement.
- Titre Crossref
- Is transvaginal mesh surgery with polytetrafluoroethylene mesh <scp>ORIHIME</scp> <sup>®</sup> feasible for anterior pelvic organ prolapse?—Randomized comparative study between <scp>ORIHIME</scp> <sup>®</sup> and <scp>Polyform™</scp>
- Date Crossref
- 05/06/2024
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Towa Pharmaceutical (Japan) pays non établi dans la noticeEntreprise
-
Asahikawa City Hospital pays non établi dans la noticeÉtablissement de santé
-
Urogynecology Center First Towakai Hospital Osaka Japan Urogynecology Center pays non établi dans la noticeÉtablissement de santé
-
Urology Department Kitasaito Hospital Asahikawa Hokkaido Japan Urology Department pays non établi dans la noticeÉtablissement de santé
Towa Pharmaceutical (Japan), Asahikawa City Hospital et Urogynecology Center — Urogynecology Center First Towakai Hospital Osaka Japan, avec 1 autre affiliation.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.